Calendario›BIIB›BIIB115
BIIB115
Ensayo de BIOGEN INC. en Voluntario sano · Atrofia muscular espinal.
- Fase
- Fase 1
- Estado
- En marcha, sin reclutar
- Participantes
- 62
- Centros
- 16
- Fin del objetivo primario
- nov 2031
Título oficial en el registro (en inglés): A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en oct 2022.
De principio a fin
- Empieza el ensayo (oct 2022)
- Hoy
- Lectura de resultados nov 2031 (prevista)
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
Partes A, B y extensión a largo plazo (LTE) de la parte B: número de participantes con acontecimientos adversos (AE) y acontecimientos adversos graves (SAE) (Part A: Up to Day 393, Part B: Up to Day 720; Part B LTE: Up to Day 2520) (del registro, en inglés)
Qué se prueba
Se estudia el fármaco BIIB115 en voluntarios sanos y en participantes con atrofia muscular espinal, centrándose en niños con esta enfermedad.
Lo que dice el documentoa study drug called BIIB115 in healthy adult male volunteers and in participants with spinal muscular atrophy (SMA). This study will focus on children with SMA.
Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroIn this study, researchers will learn about a study drug called BIIB115 in healthy adult male volunteers and in participants with spinal muscular atrophy (SMA). This study will focus on children with SMA. The main objective of the study is to learn about the safety of BIIB115 and how participants respond to different doses of BIIB115. The main question researchers want to answer is: • How many participants have adverse events and serious adverse events during the study? Adverse events are unwanted health problems that may or may not be caused by the study drug. Researchers will also learn about how the body processes BIIB115. They will do this by measuring the levels of BIIB115 in both the blood and the cerebrospinal fluid, also known as the CSF. This is the fluid around the brain and spinal cord. The study will be split into 2 parts - Part A and Part B. During Part A: * After screening, healthy volunteers will be randomly placed into 1 of 4 groups to receive either BIIB115 or a placebo. A placebo looks like the study drug but contains no real medicine. * Participants will receive a single dose of either BIIB115 or the placebo as an injection directly into the spinal canal on Day 1. * Neither the researchers nor the participants will know if the participants will receive BIIB115 or the placebo. * The Part A treatment and follow-up period will last for 13 months. * Participants will have up to 6 clinic visits and 4 phone calls. During Part B: * After screening, children with SMA will be placed into 1 of 2 groups to receive BIIB115. * The doses of each group will be decided based on the results of Part A. * Both researchers and participants will know they are receiving BIIB115. * Participants will first receive 2 total doses of BIIB115 given at 2 different times. * The Part B treatment and follow-up period will last for 24 months. * Participants will have up to 14 clinic visits and 6 phone calls. Part B Long-Term Extension: * After completing the 25 months in Part B, participants may move onto the long-term extension (LTE). * They will receive 5 more doses of BIIB115 at different times. * The Part B LTE treatment and follow-up will last for 60 months. * Participants will have up to 12 more clinic visits and 19 phone calls. In both Part A and Part B, participants will stay in the clinic for 24 hours after each dose so that researchers can check on their health. This 24-hour stay will not be required for the Part B LTE period.
Sigue a BIIB y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Más ensayos de BIIB
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Diranersen · CELIA | Fase 2 | En marcha, sin reclutar | mar 2026 (real) |
| BIIB142 | Fase 1 | Reclutando pacientes | ago 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · TOPAZ-2 | Fase 3 | En marcha, sin reclutar | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · TOPAZ-1 | Fase 3 | En marcha, sin reclutar | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · AMETHYST | Fase 2/3 | En marcha, sin reclutar | oct 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Felzartamab · TRANSCEND | Fase 3 | En marcha, sin reclutar | dic 2026 (prevista) |
Todos los de BIIB, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05575011), actualizada en oct 2026.